Pooja Amarapurkar , Levard Roberts , Jose Navarrete , Fuad El Rassi
{"title":"镰状细胞病和肾脏","authors":"Pooja Amarapurkar , Levard Roberts , Jose Navarrete , Fuad El Rassi","doi":"10.1053/j.ackd.2022.03.004","DOIUrl":null,"url":null,"abstract":"<div><p><span><span>Sickle cell disease<span><span> causes several kidney manifestations. They include defects in urine concentration, impaired handling of potassium and hydrogen ion, </span>albuminuria, </span></span>acute kidney injury<span>, and chronic kidney disease<span> to name a few. Glomerular hyperfiltration<span><span>, tubular hyperfunctioning, endothelial damage from repeated sickling and vaso-occlusive episodes, and iron-induced proinflammatory changes in the glomerular mesangium and tubulointerstitium are some of the mechanisms of kidney damage. Albuminuria is one of the most and common clinical features of </span>kidney disease and progresses with age. Kidney disease </span></span></span></span>in patients<span><span> with sickle cell is associated with increased mortality. Annual screening for </span>proteinuria<span><span> starting at age 10 years and limiting the use of nonsteroidal anti-inflammatory agents and the use of angiotensin-converting enzyme inhibitors may help in early detection and delaying the progression of kidney disease. Adequate hydration, angiotensin-converting enzyme inhibitors, and adequate control of sickle cell are the main stay of treatment for albuminuria. The hemoglobin goal for patients with </span>sickle cell nephropathy is lesser (10 g/dL) than that for patients with chronic kidney disease due to other causes given that a higher hemoglobin level increases viscosity and the risk of precipitating vaso-occlusive episodes. A multidisciplinary approach is recommended for managing patients with sickle cell and kidney diseases.</span></span></p></div>","PeriodicalId":7221,"journal":{"name":"Advances in chronic kidney disease","volume":"29 2","pages":"Pages 141-148.e1"},"PeriodicalIF":2.0000,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"Sickle Cell Disease and Kidney\",\"authors\":\"Pooja Amarapurkar , Levard Roberts , Jose Navarrete , Fuad El Rassi\",\"doi\":\"10.1053/j.ackd.2022.03.004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p><span><span>Sickle cell disease<span><span> causes several kidney manifestations. They include defects in urine concentration, impaired handling of potassium and hydrogen ion, </span>albuminuria, </span></span>acute kidney injury<span>, and chronic kidney disease<span> to name a few. Glomerular hyperfiltration<span><span>, tubular hyperfunctioning, endothelial damage from repeated sickling and vaso-occlusive episodes, and iron-induced proinflammatory changes in the glomerular mesangium and tubulointerstitium are some of the mechanisms of kidney damage. Albuminuria is one of the most and common clinical features of </span>kidney disease and progresses with age. Kidney disease </span></span></span></span>in patients<span><span> with sickle cell is associated with increased mortality. Annual screening for </span>proteinuria<span><span> starting at age 10 years and limiting the use of nonsteroidal anti-inflammatory agents and the use of angiotensin-converting enzyme inhibitors may help in early detection and delaying the progression of kidney disease. Adequate hydration, angiotensin-converting enzyme inhibitors, and adequate control of sickle cell are the main stay of treatment for albuminuria. The hemoglobin goal for patients with </span>sickle cell nephropathy is lesser (10 g/dL) than that for patients with chronic kidney disease due to other causes given that a higher hemoglobin level increases viscosity and the risk of precipitating vaso-occlusive episodes. A multidisciplinary approach is recommended for managing patients with sickle cell and kidney diseases.</span></span></p></div>\",\"PeriodicalId\":7221,\"journal\":{\"name\":\"Advances in chronic kidney disease\",\"volume\":\"29 2\",\"pages\":\"Pages 141-148.e1\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2022-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in chronic kidney disease\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1548559522000532\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in chronic kidney disease","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1548559522000532","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
Sickle cell disease causes several kidney manifestations. They include defects in urine concentration, impaired handling of potassium and hydrogen ion, albuminuria, acute kidney injury, and chronic kidney disease to name a few. Glomerular hyperfiltration, tubular hyperfunctioning, endothelial damage from repeated sickling and vaso-occlusive episodes, and iron-induced proinflammatory changes in the glomerular mesangium and tubulointerstitium are some of the mechanisms of kidney damage. Albuminuria is one of the most and common clinical features of kidney disease and progresses with age. Kidney disease in patients with sickle cell is associated with increased mortality. Annual screening for proteinuria starting at age 10 years and limiting the use of nonsteroidal anti-inflammatory agents and the use of angiotensin-converting enzyme inhibitors may help in early detection and delaying the progression of kidney disease. Adequate hydration, angiotensin-converting enzyme inhibitors, and adequate control of sickle cell are the main stay of treatment for albuminuria. The hemoglobin goal for patients with sickle cell nephropathy is lesser (10 g/dL) than that for patients with chronic kidney disease due to other causes given that a higher hemoglobin level increases viscosity and the risk of precipitating vaso-occlusive episodes. A multidisciplinary approach is recommended for managing patients with sickle cell and kidney diseases.
期刊介绍:
The purpose of Advances Chronic Kidney Disease is to provide in-depth, scholarly review articles about the care and management of persons with early kidney disease and kidney failure, as well as those at risk for kidney disease. Emphasis is on articles related to the early identification of kidney disease; prevention or delay in progression of kidney disease